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REGULAR ARTICLE

Red blood cell adhesion to ICAM-1 is mediated by ﬁbrinogen and is
associated with right-to-left shunts in sickle cell disease
Erdem Kucukal,1 Yuncheng Man,1 Erina Quinn,2 Neil Tewari,1 Ran An,1 Anton Ilich,3 Nigel S. Key,3 Jane A. Little,3 and Umut A. Gurkan1,4
1

Key Points

• Red blood cells from
patients with sickle cell
disease adhere to
ICAM-1, which is associated with hemolysis
and history of right-toleft shunts.
• Red blood cell adhesion to ICAM-1 in
SCD is mediated by
membrane-bound fibrinogen, which acts as
a bridging molecule.

Sickle cell disease (SCD), which aﬄicts 100 000 Americans, as well as millions worldwide, is
associated with anemia, lifelong morbidity, and early mortality. Abnormal adhesion of
sickle red blood cells (RBCs) to activated vascular endothelium may contribute acutely to the
initiation of painful vaso-occlusive crises and chronically to endothelial damage in SCD.
Sickle RBCs adhere to activated endothelium through several adhesion mechanisms. In this
study, using whole blood from 17 people with heterozygous SCD (HbS variant) and 55 people
with homozygous SCD (HbSS) analyzed in an in vitro microﬂuidic assay, we present
evidence for the adhesion of sickle RBCs to immobilized recombinant intercellular adhesion
molecule 1 (ICAM-1). We show that sickle RBC adhesion to ICAM-1 in vitro is associated with
evidence of hemolysis in vivo, marked by elevated lactate dehydrogenase levels,
reticulocytosis, and lower fetal hemoglobin levels. Further, RBC adhesion to ICAM-1
correlates with a history of intracardiac or intrapulmonary right-to-left shunts. Studies of
potential ICAM-1 ligands on RBC membranes revealed that RBC–ICAM-1 interactions were
mediated by ﬁbrinogen bound to the RBC membrane. We describe, for the ﬁrst time, RBC
rolling behavior on ICAM-1 under high shear rates. Our results suggest that ﬁrm adhesion of
sickle RBCs to ICAM-1 most likely occurs in postcapillary venules at low physiological shear
rates, which is facilitated by initial rolling in high shear regions (eg, capillaries). Inhibition of
RBC and ICAM-1 interactions may constitute a novel therapeutic target in SCD.

Introduction
Sickle cell disease (SCD) leads to the production of abnormally adhesive and stiff red blood cells
(RBCs) due to a mutation in the b-globin chain of hemoglobin.1 The clinical manifestations of SCD are
mediated, in part, by abnormal cellular adhesion in the microvasculature. Impedance of microcirculatory
flow is further disrupted in a locally hypoxic environment, in which sickle hemoglobin polymerizes into
long and stiff chains under low oxygen tension, ultimately resulting in the formation of nondeformable
RBCs.2-5 In SCD, abnormal cellular adhesion and the presence of highly rigid RBCs contribute to
episodic and painful vaso-occlusive crises (VOCs), cumulative vasculopathy, and significant morbidity
and early mortality.6
To date, a large group of endothelial- and subendothelial-associated adhesion molecules are
recognized as mediators of sickle RBC adhesion to the vascular wall, including laminin,7
fibronectin,8 thrombospondin,9 VCAM-1,10 and P-selectin.11 However, it is still not clear which of, or
to what degree, these molecules play a role in the progression of vaso-occlusion or endothelial
activation. In an early study, there was a significant correlation between hypoxia-induced RBC adhesion
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Despite the recent efforts to better understand RBC adhesion
mechanisms in SCD, there are adhesive ligands whose role in
enhancing adhesion of sickle RBCs to the vascular wall, such
as immobilized recombinant intercellular adhesion molecule 1
(ICAM-1; notwithstanding its extensively characterized contribution
to WBC-endothelium interactions) have yet to be characterized.
Firm adhesion of neutrophils to the endothelium requires the
expression of ICAM-1, because neutrophils tend to have a rolling
behavior on selectins rather than establishing a firm attachment.18
Neutrophil adhesion to ICAM-1 is mediated through b2 integrins
(leukocyte function-associated antigen-1 [LFA-1] and macrophage
antigen 1 [MAC-1]) and may be modulated by soluble fibrinogen.19,20
However, there has not been a systematic exploration of the
adhesive interactions between sickle RBCs and ICAM-1, despite
the abundant expression of ICAM-1 on the chronically activated and
inflamed vasculature of SCD patients.21
In this study, we examined the adhesion of sickle RBCs from SCD
subjects to immobilized ICAM-1 in microphysiological flow conditions utilizing an in vitro microfluidic adhesion assay. For the first
time, we demonstrate that ICAM-1 supports the adhesion of sickle
RBCs, in a subject-specific manner; adhesion of RBCs from
homozygous subjects (HbSS) strongly correlated with high-grade
hemolysis and a history of intracardiac or intrapulmonary right-to-left
shunts. In particular, RBCs from subjects with HbSS and evidence
for hemolysis and inflammation (elevated lactate dehydrogenase
[LDH] levels, absolute reticulocyte counts [ARCs], and WBC
count) have an increased propensity for adhesion. Notably, sickle
RBC adhesion to ICAM-1 was mediated via fibrinogen, which
forms intercellular bridges. Lastly, we observed that a fraction
of adherent RBCs exhibited rolling motion at high shear rates
and did not disassociate from the immobilized protein, suggesting
a novel mechanism by which RBCs may contribute to the initiation
of VOC events in SCD.

syringe pump (New Era NE-300; New Era Pump Systems,
Farmingdale, NY). To remove the nonadherent cells, another
syringe filled with wash buffer (1% bovine serum albumin and
0.09% sodium azide in 13 phosphate buffered saline [PBS])
was connected to the microchannels, and the buffer solution was
injected at 10 mL/min, corresponding to a wall shear stress of
1 dyne/cm2, until all nonadherent cells had been cleared. Phasecontrast images of the microchannel surface were obtained
using an inverted microscope at 203. Quantification of ICAM1–adherent RBCs was performed manually using Adobe Photoshop CS5 (Adobe, San Jose, CA) within a rectangular field of
view (fov) with a surface area of 32 mm2.

Inhibition experiments
For the inhibition studies, whole HbSS blood samples were mixed
with a monoclonal mouse antibody against human a4b1 or LFA-1
at a final antibody concentration of 50 mg/mL and incubated at 37°C for 1 hour prior to the adhesion experiments.
As a control, samples were treated with the same concentration of
isotype-control mouse immunoglobulin G1 for the same duration.
Anti-human LFA-1 antibody and the isotype-control mouse immunoglobulin G were from BioLegend (San Diego, CA). Anti-human
a4b1 antibody was purchased from Abcam (Cambridge, MA). To
block the b2-associated adhesion pathways, a recombinant human
b2 protein solution (Novus Biologicals, Centennial, CO) was
perfused into ICAM-1–functionalized microchannels and incubated
for 1 hour at 37°C. Before starting the adhesion experiments, the
microchannels were rinsed 3 times with PBS. Similarly, to test the
inhibitory effect of fibrinogen (Enzo Life Sciences, Farmingdale, NY)
or low molecular weight heparin (LMWH; AMSBIO, Cambridge,
MA), ICAM-1–functionalized microchannels were injected with
fibrinogen (range, 1-20 mg/mL) or LMWH (range, 0.1-5 mg/mL).
After an hour at 37°C, the microchannels were rinsed with PBS
3 times, and adhesion was assessed as above.

Statistical methods
Minitab 19 (Minitab, State College, PA) was used to analyze the
results. A normality test was performed to determine whether the
variables were normally distributed. Because of the largely nonnormally distributed variables, Mann-Whitney U tests were used to
compare 2 groups, and Kruskal-Wallis tests with Dunn’s correction
were used to compare multiple groups, unless stated otherwise.
K-means clustering analysis was performed to identify distinct
subject subpopulations based on hemolysis biomarkers. Throughout this article, the error bars represent 6 standard error of the
mean (SEM). P , .05 was considered statistically significant.

Results

Flow adhesion experiments

Abnormal sickle RBC adhesion to ICAM-1 is
heterogeneous in a clinically diverse population
with SCD

Fabrication and functionalization of the microfluidic channels were
carried out as described in supplemental Materials. Functionalized
microchannels were connected to blood-containing syringes
through 40-cm inlet tubing. A total of 15 mL of whole blood sample
was perfused into the microchannels at an approximate shear
stress of 1 dyne/cm2, corresponding to the typical shear stress
observed in postcapillary venules, via a constant displacement

We analyzed the ability of RBCs to adhere to ICAM-1 using whole
blood samples from individuals with (HbSS, HbS variant) or without
(HbAA) SCD in a physiologically relevant in vitro microfluidic
adhesion platform. Our results showed that HbSS RBCs had
significantly greater adhesion to immobilized ICAM-1 than did HbS
variant RBCs or HbAA RBCs (Figure 1D; mean adhesion 6
standard deviation [SD] 5 1486 6 3312 per fov for HbSS, 54 6 59

Methods
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and VCAM-1 expression levels on the endothelial cell surface but
not under normoxic conditions.10 Notably, only the adhesion of lessdense RBCs (reticulocytes) was mediated via VCAM-1, suggesting
an adhesion pathway involving a4b1, which has also been shown to
mediate sickle reticulocyte adhesion to fibronectin.8 White et al
recently demonstrated that white blood cell (WBC) and RBC
adhesion to VCAM-1 correlated positively with the frequency of
vaso-occlusive events in SCD.12 Sickle RBC adhesion to laminin
has recently been reported to have clinical implications in normoxic
and hypoxic conditions,3,13,14 consistent with the earlier studies that
pointed to a link between RBC adhesion and clinical severity of the
disease.15,16 In concert with these findings, it was recently shown
that a P-selectin inhibitor significantly diminished the frequency of
VOCs in SCD patients owing to the multifaceted role of P-selectin
in SCD pathophysiology.17

Figure 1. The microfluidic assay used to assess

A

adhesion of sickle RBCs to immobilized

C

ICAM-1 under physiological flow conditions. (A)
Assembled microdevice containing 3 separate microchannels, each functionalized with ICAM-1. Arrow
indicates the flow direction. (B) Recombinant human
ICAM-1 protein was immobilized on the microchannel
surface via a cross-linker agent, GMBS, to ensure
consistent protein coverage throughout the microchannel, as well as to prevent protein dissociation
from the surface at high shear rates. (C) Representa(upper panel). Enlarged images of the green boxes
are shown (lower panel). Adherent sickle RBC populations possessed distinct morphologies: (i) RBC
with a characteristic biconcave morphology and elon-

B

gated elliptic shape, (ii) RBC with a nearly absent biconcave morphology and further impaired elliptic
shape, (iii) RBC with no biconcave morphology and
elongated elliptic shape, (iv) highly sickled RBC with
no biconcave morphology. (D) The number of adherent RBCs was significantly greater in samples from
subjects with HbSS . HbS variant . HbAA. The
horizontal lines represent the means; ‘‘n’’ represents

ICAM-1

the number of blood samples tested. A total of 106
blood samples were tested from 55 subjects with

Number of adherent RBCs to I CAM-1

D

HbSS SCD. The scale bars are 5 mm.

p0.001

25000

p=0.002

20000

p0.001

14000
7500
5000
2500
0
HbAA
n=10

HbS-variants
n=17

HbSS
n=106

per fov for HbS variant, and 3.5 6 1.4 per fov for HbAA, P , .005).
We also observed subject-specific and heterogeneous adhesion
profiles for HbSS RBCs, ranging between 6 and 19 495 for the
entire study population with homozygous SCD (n 5 55; mean
adhesion 1486 6 3312 per fov).

Sickle RBC adhesion to ICAM-1 is associated with
clinical biomarkers of hemolysis
We found an association between HbSS RBC adhesion to ICAM-1
and clinical variables, in samples obtained at the clinical steadystate. We performed a k-means clustering analysis based on
subject LDH levels and ARCs, which resulted in 2 distinct HbSS
subgroups (Figure 2A). We found that RBCs from samples in group
1 (n 5 34; lower LDH and lower ARC laboratory profiles) had
significantly less adhesion to ICAM-1 compared with RBCs from
3690
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samples in group 2 (n 5 21; higher LDH levels and higher ARC
laboratory profiles) consistent with hemolysis (Figure 2B; 453 6
199 per fov vs 3159 6 1038 per fov; mean adhesion 6 SEM,
respectively; P 5 .002). These findings suggest an association
between RBC adhesion to the vascular bed, hemolysis, and
shortened RBC half-life. In addition, we found an association
between HbSS RBC adhesion to ICAM-1 and WBC count (Figure
2C-D). Subjects with an elevated WBC count (.11 3 109 per liter)
exhibited significantly higher RBC adhesion compared with those
with a normal WBC count (Figure 2D; 2532 6 1017 per fov vs
789 6 265 per fov; mean adhesion 6 SEM, respectively; P 5 .02).
The clinical variables of subjects in group 1 and group 2 are
summarized in Table 1.
Next, we examined associations between fetal hemoglobin (HbF)
and RBC adhesion to ICAM-1 (Figure 3A-B). We assessed RBC
11 AUGUST 2020 x VOLUME 4, NUMBER 15
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tive image obtained following an adhesion experiment

A

B
Number of adherent RBCs to I CAM-1
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C
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D
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Figure 2. Adhesion of HbSS RBCs to immobilized ICAM-1 in vitro is associated with subject hematological parameters. (A) Subjects were categorized into 2
groups based on their LDH levels and ARCs; group 1 (d) had higher LDH and ARCs. The categorization was performed based on the k-means clustering method. The shaded
green and blue regions indicate reference ranges (normal) for LDH and ARC levels, respectively. (B) Subjects in group 2 had significantly higher RBC adhesion levels compared with the patients in group 1 (mean, 3159 6 4758 vs 453 6 1159, respectively). (C) There is a positive correlation between adherent RBC numbers and WBC counts.
The shaded blue region represents the normal WBC range in healthy adults. (D) Subjects with clinically high WBC counts (.11 3 109/L) have significantly greater RBC
adhesion to ICAM-1 in vitro. The horizontal lines in panels B and D represent the mean; ‘‘n’’ represents the number of subjects tested. The P values were calculated using the
Mann-Whitney nonparametric U test. PCC, Pearson’s correlation coefficient.

adhesion with respect to subjects’ HbF levels, with a cutoff value
of 8.6%, which was associated with improved life expectancy and
a decrease in VOCs in natural history studies.22 We found that
HbSS RBCs from subjects with higher HbF levels (n 5 18) had
significantly lower adhesion to ICAM-1 compared with those with
lower HbF levels (n 5 37) (Figure 3C; 283 6 107 per fov vs
2127 6 649 per fov; mean adhesion 6 SEM, respectively; P 5
.007). Moreover, 14 of 37 subjects with lower HbF levels
(,8.6%) had RBC adhesion that was higher than the mean
adhesion level, whereas only 1 of 19 subjects had HbF levels .
8.6%. Hydroxyurea (HU) treatment had a significant impact on
HbF levels in our cohort (P , .001, x2 test). Fourteen of 18
(77.8%) subjects with an HbF level . 8.6% were on HU
compared with only 5 of 37 subjects (13.5%) with an HbF
level , 8.6%. Of note, RBC adhesion did not correlate with
subjects’ hemoglobin A levels (ie, prior transfusions; data not
shown).
11 AUGUST 2020 x VOLUME 4, NUMBER 15

History of intracardiac/intrapulmonary right-to-left
shunts is associated with higher RBC adhesion
to ICAM-1
We next analyzed the adhesion data for select clinical comorbidities, including intracardiac or intrapulmonary shunts, concurrent
nephropathy, and history of acute chest syndrome (ACS). Our
results showed that people with HbSS and a history of right-to-left
shunts had significantly higher RBC adhesion to ICAM-1 compared
with people with HbSS and no history of right-to-left shunts
(Figure 4; 2184 6 717 per fov vs 515 6 738 per fov; mean
adhesion 6 SEM, respectively; P 5 .03). Although RBC adhesion
was typically higher for subjects with a history of nephropathy or
ACS compared with those without, we did not detect a statistically
significant difference. These results suggest that higher RBC
adhesion to ICAM-1 may be a surrogate biomarker of right-to-left
intrapulmonary or intracardiac shunts in people with HbSS.
RBC ADHESION TO ICAM-1 IN SICKLE CELL DISEASE
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Absolute reticulocyte count (109/L)

1000

Table 1. Clinical variables of the tested subjects with HbSS SCD
Group 1 (n 5 34)

Group 2 (n 5 21)

37.8 6 13.6

35.9 6 13.0

.628**

8.6 6 1.4

8.6 6 1.3

.965**

96.7 6 14.2

92.6 6 5.4

.222*

313.7 6 140.9

364.3 6 89.4

.147*
.002*

Age, y
Hemoglobin, g/dL
Mean corpuscular volume, fL
Platelets, 3109/L
WBC count, 310 /L

P

12.7 6 3.8

5514 6 2303

7359 6 2841

.014*

ARC, 3109/L

214.7 6 89.1

482.2 6 174.9

<.001*

LDH, U/L

271.9 6 64.0

510.0 6 200.2

<.001*

2680.2 6 2626.3

1920.4 6 2179.3

.472*

Hemoglobin S, %

Ferritin, mg/L

58.5 6 23.7

56.5 6 20.2

.523*

Hemoglobin A, %

25.8 6 24.6

30.0 6 21.8

.601*

Hemoglobin F, %

8.2 6 7.6

4.1 6 4.3

.143*

A total of 106 blood samples were obtained from 55 patients with homozygous HbSS (29 males and 26 females); the mean value was used for a subject tested more than once. Data are
mean 6 standard deviation. P values that represent a statistically significant difference between group 1 and 2 are denoted with boldface.
*Nonparametric Mann-Whitney U test.
**Parametric 1-way analysis of variance (ANOVA).

Longitudinal monitoring of RBC adhesion to ICAM-1
We obtained multiple data points from 12 individuals with HbSS
SCD at steady-state to monitor the variation in RBC adhesion and
its association with clinical biomarkers (LDH, ARC, and WBC
count) over time. Four subjects had very low adhesion levels, which
did not change over time (,50 RBCs). Nineteen data points were
obtained from 8 people: 6 subjects had RBC adhesion data from
2 time points, and the other 2 subjects had data from 3 and 4 time
points (supplemental Figure 1). Between each time point, or
interval, we determined whether subjects’ RBC adhesion and
clinical biomarkers changed or remained the same, with a total of 11
evaluable intervals (ie, 1 interval for subjects with 2 time points and
2 and 3 intervals for subjects with 3 and 4 time points, respectively).
We found that an increase or decrease in LDH levels and ARC was
typically accompanied by an increase or decrease in RBC
adhesion, whereas WBC counts did not seem to correlate with

HbSS RBC adhesion to ICAM-1 is mediated by
fibrinogen, which acts as a bridging molecule
between RBCs and immobilized ICAM-1
To determine possible mediators of HbSS RBC adhesion to
immobilized ICAM-1, we performed adhesion-inhibition experiments. First, we inhibited a4b1 integrin on the surface of RBCs to

B
Number of adherent RBCs to I CAM-1

Number of adherent RBCs to I CAM-1

A

RBC adhesion. A change in LDH levels and ARC was reflected by
a change in RBC adhesion for 8 of 11 (73%) intervals and 7 of 11
(64%) intervals, respectively. On the other hand, WBC counts
reflected a change in RBC adhesion in only 3 of 11 intervals (27%).
These results suggest that RBC adhesion may correlate with LDH
and ARC over time. Nevertheless, it is still possible to detect
changes in RBC adhesion, despite stable LDH levels and ARC,
indicating that different factors could be at play with regard to RBC
adhesion at different time points.

30000
20000
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PCC = -0.24

4000

P = 0.06

2000
0
0

5

10

15

HbF (%)

20

25

30000

p  0.05

20000
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4000
2000
0
HbF!8.6
n=18

Hb8.6
n=37

Figure 3. Adhesion of HbSS RBCs to immobilized ICAM-1 in vitro correlates clinically with HbF levels. (A) There is an inverse relationship between RBC adhesion
to ICAM-1 and HbF level. The P value was based on 1-way ANOVA. (B) Subjects with higher HbF levels (using a previously defined ameliorative cutoff of 8.6%22) had
significantly lower numbers of adherent RBCs compared with those with lower HbF levels. The horizontal lines represent the means; ‘‘n’’ represents the number of subjects.
The Mann-Whitney nonparametric U test was used to calculate the P value in panel B. PCC, Pearson’s correlation coefficient.
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9.6 6 3.2

Absolute neutrophil count, 3106/L

9

Figure 4. Association of RBC adhesion to ICAM-1 with select
clinical phenotype in HbSS SCD. Subjects with a history of
intracardiac or intrapulmonary shunt have significantly higher RBC

4000

adhesion compared with those with no history of shunt. A history of

p=0.03

ns

ns

nephropathy or ACS does not have a significant association with
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Shunt
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Nephropathy
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b2-associated integrin in WBC–ICAM-1 interactions. Again, we
found that neither the treatment of the blood samples with
anti–LFA-1 antibodies nor incubation of the ICAM-1–immobilized
microchannels with recombinant human b2 protein prior to sample
application had an inhibitory effect on the adhesion of HbSS RBCs
to ICAM-1 (Figure 5A). Therefore, we used fibrinogen to block the

assess the adhesion of reticulocytes that were previously shown
to adhere to fibronectin and VCAM-1 through a4b1. However,
inhibition of a4b1 integrin did not result in reduced RBC adhesion
(Figure 5A). Next, we tested whether HbSS RBC adhesion to
ICAM-1 is mediated by integrin-type receptors on the red cell
membrane, considering the extensive characterization of the role of

% of adherent RBCs to I CAM-1

A
150

100
Figure 5. The adhesion of HbSS RBCs to immo-

50

bilized ICAM-1 is mediated by fibrinogen and is
inhibited by LMWH. (A) Mean percentages of RBCs
adherent to immobilized ICAM-1 following the treat-
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antibodies or the treatment of microchannels with
recombinant human b2 protein in 5 experiments. With

Inhibition molecule

vehicle treatment, a mean of 100% of RBCs adhered
to immobilized ICAM-1. No significant reduction in

C
150

p0.01
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served (P . .05). (B) Treatment of microchannels with
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fibrinogen decreased HbSS RBC adhesion to ICAM-1
in a concentration-dependent manner. Shown are

100

mean percentages of adherent RBCs after treatment
with 1, 5, 10, or 20 mg/mL fibrinogen (n 5 5). (C)
Treatment of blood samples with LMWH significantly

50

inhibited HbSS RBC adhesion to ICAM-1. Shown are
mean percentages of adherent RBCs following pretreatment with 0.1, 1, or 5 mg/mL LMWH in 5 experi-

0

0
0

1

5

10

20

0

Fibrinogen concentration (mg/mL)
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1

LMWH concentration (Pg/mL)

5

ments. The P values were calculated using 1-way
ANOVA with the Dunnett post hoc test. Error bars
represent 6 SEM.

11 AUGUST 2020 x VOLUME 4, NUMBER 15

RBC ADHESION TO ICAM-1 IN SICKLE CELL DISEASE

3693

Downloaded from http://ashpublications.org/bloodadvances/article-pdf/4/15/3688/1755061/advancesadv2020001656.pdf by guest on 07 December 2022

Number of adherent RBCs

RBC adhesion levels. The P value was calculated using a 2-sample
Student t test. ns, not significant.
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Figure 6. Rolling adhesion of HbSS RBCs onto immobilized ICAM-1 under flow conditions. The data shown are the mean percentages of adherent or rolling RBCs
onto immobilized ICAM-1 and the mean rolling velocities under shear rates of 500, 1000, 2000, 3000, 4000, and 5000 s21. A mean of 100% of HbSS RBCs adhered to
immobilized ICAM-1 (including rolling adhesion and firm adhesion). (A) The number of adherent RBCs to immobilized ICAM-1 decreased with increasing shear rates. Shown
are mean percentages of adherent RBCs (n 5 5). (B) Two overlapped frames, taken 1 second apart, extracted from a video depicting cell rolling behavior. (C) The number of
rolling RBCs increased with increasing shear rates (n 5 5). (D) The velocities of rolling RBCs on immobilized ICAM-1 increased with increasing shear rates (n 5 5). Error bars
represent 6 SEM.

fibrinogen-binding domain of the immobilized ICAM-1 on the
channel surface to prevent sample plasma fibrinogen from
enhancing adhesive interactions during blood flow. Notably,
treatment of microchannels with fibrinogen significantly decreased
RBC adhesion in a concentration-dependent manner (Figure 5B).
It has been reported that plasma fibrinogen levels were in the range
of 2 to 5.5 mg/mL for healthy subjects and 3 to 11.5 mg/mL
for subjects with HbSS SCD.23 Therefore, we used 4 fibrinogen
concentrations to simulate physiologic and pathophysiologic conditions: 1, 5, 10, and 20 mg/mL. Incubation of ICAM-1–immobilized
microchannels with 1 mg/mL of fibrinogen did not inhibit RBC
adhesion, whereas using a fibrinogen concentration of 5 mg/mL
blocked adhesion by ;50% (Figure 5B), suggesting that supranormal fibrinogen levels in HbSS blood samples may decrease
RBC adhesion to ICAM-1. Because LMWH can bind to fibrinogen,
we next treated whole blood samples with LMWH (1:1 volume to
volume ratio) at concentrations of 0.1, 1, and 5 mg/mL, all of which
significantly blocked RBC adhesion to ICAM-1 (Figure 5C); on the
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other hand, preincubation of microfluidic channels with LMWH had
no effect (data not shown). These findings suggest a mediating role
for plasma fibrinogen in HbSS RBC adhesion to ICAM-1.

HbSS RBCs roll on ICAM-1 at higher shear rates and
establish a firm attachment at lower shear rates
We observed that the total number of adherent RBCs decreased
with increasing shear rate (Figure 6A), whereas adherent RBCs
persisted even after exposure to extreme shear rates (up to
5000 s21). We also observed a distinct motion of adherent RBCs,
depending on flow shear rate. Some of the adherent RBCs
exhibited rolling adhesion on ICAM-1, particularly at higher shear
rates (Figure 6B), and the percentages of rolling RBCs increased
at shear rates of 3000, 4000, and 5000 s21 compared with those
at 500, 1000, and 2000 s21 (Figure 6C). Similarly, RBC rolling
velocities increased at higher flow shear rates, with the maximum
occurring at 5000 s21 (Figure 6D), suggesting that the characteristic
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adhesion behavior shown herein may prevent physiological flow rates
from removing persistently attached RBCs in the microvasculature.

Discussion

Endothelial activation has been thought to have an important role in
SCD pathology and VOC.28 There are several adhesion molecules
that have been associated with an activated phenotype in SCD,
such as ICAM-1, VCAM-1, E-selectin, and P-selectin.29,30 These
adhesion molecules mediate the attachment and movement of
blood cells to the endothelium and into peripheral tissue while
increasing microvascular permeability. ICAM-1 expression has been
shown to be induced by various inflammatory signaling pathways.31
Although the interactions between WBCs and ICAM-1, abundantly
found on the activated endothelial lining, have been well characterized, the role of ICAM-1 in supporting HbSS RBC adhesion to
ECs has never been identified. Here, our results demonstrated
significant HbSS RBC adhesion to immobilized ICAM-1 presenting
unique dynamics of motion, which were heterogeneous and subjectspecific. In our previous work, we correlated HbSS RBC adhesion to
laminin with increased hemolysis and inflammation.13,25,32 High LDH
levels and ARCs have been suggested as markers of hemolysisassociated endothelial dysfunction and disease severity.33 On the
other hand, ICAM-1 is located directly on the endothelium, which may
result in a more physiologically meaningful representation of cellular
adhesion to vascular endothelium. Our results show that increased
RBC adhesion to ICAM-1 correlates with hemolysis and a history of
right-to-left shunts. Moreover, variations in RBC adhesion to ICAM-1
over time appear to correlate with LDH and ARC: an increasing or
decreasing level of LDH or ARC corresponds to an increase or
decrease in RBC adhesion. These observations are consistent with
the “hyperhemolytic paradigm” that establishes that hemolysis in
SCD increases endothelial dysfunction along with increased free
plasma hemoglobin and NO biodeficiency and consumption.
HbF is one of the most studied genetic modulators of SCD because
of its protective role in the disease. An increase in HbF levels
correlates with improved survival and a milder disease phenotype,
as evidenced by the lower frequency of VOCs and decreased
mortality.22,34 Here, we found that HbF was inversely related to the
adhesion of RBCs to ICAM-1. Interestingly, HbF levels seem to
have a stronger effect than transfusions on decreasing RBC
adhesion. Our data indicated that, even subjects with relatively
lower HbS levels may exhibit enhanced RBC adhesion to ICAM-1
(data not shown). Because the majority of subjects with higher HbF
levels were on HU therapy, we cannot rule out the potential direct
impacts of HU on RBC adhesion, independent of an HbF-related
mechanism. For instance, Bartolucci et al showed that HU led to
diminished phosphorylation of Lu/BCAM, regardless of the HbF
expression levels, thereby decreasing HbSS RBC adhesion to
laminin.35 It is also possible that downregulation of several adhesion
11 AUGUST 2020 x VOLUME 4, NUMBER 15

Although adhesion of Plasmodium falciparum–infected RBCs
(iRBCs) to ICAM-1 has been well established,37 HbSS RBC
adhesion to ICAM-1 has not yet been documented. It has been
shown that P falciparum erythrocyte membrane protein 1 is
implicated in iRBC adhesion to ICAM-1 as the result of a binding
site on the first domain of ICAM-1, which overlaps with the
fibrinogen binding domain.38 iRBCs were shown to bind to
ICAM-1 at a site that was distinct from LFA-1, MAC-1, and human
rhinovirus.39 Further, blocking the fibrinogen binding site of ICAM-1
diminished iRBC adhesion to ICAM-1 in static and flow adhesion
assays. Fibrinogen plays a vital role in the establishment of
intercellular bridging between WBCs and ICAM-1, independently
from LFA-1–and MAC-1–related pathways. We hypothesized that
adhesion of HbSS RBCs to immobilized ICAM-1 in our microfluidic
model was driven through a pathway involving plasma fibrinogen,
because the HbSS RBC membrane lacks b2 integrins. Indeed,
mixing the blood samples with an antibody against LFA-1 or
incubating the ICAM-1–immobilized microchannels with b2 integrin
did not have any effect on RBC adhesion. Similarly, blocking the
a4b1-dependent pathway did not have any effect on RBC adhesion,
suggesting that little or no contribution was made by reticulocytes.
Our results reveal that HbSS RBC adhesion was significantly
attenuated upon fibrinogen pretreatment of the microchannels
immobilized with ICAM-1 in a concentration-dependent manner.
These results indicate that HbSS RBCs do not directly interact with
ICAM-1; rather, membrane-bound fibrinogen, which was characterized previously,40 triggers the adhesive connection by forming an
intercellular bridge. To further support this, we incubated whole
blood samples with varying concentrations of LMWH, which has
been shown to bind to fibrinogen, prior to the flow adhesion
experiments. Notably, LMWH pretreatment of blood samples, but
not of the microchannels themselves, significantly blocked RBC
adhesion to ICAM-1, even at very low doses (ie, .80% inhibition at
0.1 mg/mL).
Although elevated plasma fibrinogen levels are linked to an
increased risk for thrombosis,41 they may also interfere with ICAM1–mediated RBC adhesion to decrease the frequency of VOC
episodes. Upregulation of ICAM-1 through the vascular endothelium is triggered by various plasma cytokines and takes place at
different levels, depending on the origin of the tissue. Therefore,
a high fibrinogen level may alleviate cellular adhesion at sites
where ICAM-1 is predominantly expressed while increasing the
likelihood of thrombotic complications. Our results suggest that
novel therapeutic approaches targeting the fibrinogen binding
domain of ICAM-1 may decrease ICAM-1–mediated HbSS RBC
adhesion.
Furthermore, our results revealed that interactions analogous to
leukocyte rolling on endothelium occur when HbSS RBCs bind to
ICAM-1 at high shear rates. Similar rolling behavior of iRBCs
interacting with ICAM-1 has also been documented.42,43 In the
case of leukocytes, initial capture and rolling are established
through receptors from the selectin family (eg, E-selectin), after
RBC ADHESION TO ICAM-1 IN SICKLE CELL DISEASE
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SCD limits the lifespan of millions of individuals worldwide through
a single hemoglobin mutation.24 Disease severity has been linked
to abnormal RBC adhesion to the vascular endothelium, thereby
contributing acutely to VOC and chronically to endothelial
activation.15,25 Although the pathways leading to aberrant RBC
adhesion to vascular endothelium and associated proteins are
complex and have not been fully explicated yet, RBC adhesion
plays a pivotal role in the initiation and propagation of unpredictable VOC episodes, thereby contributing to the pathophysiology
of SCD.15,26,27

molecules, such as CD36 and a4b1,36 could result in attenuated
overall RBC adhesion. Nevertheless, a direct inhibitory effect of
HbF on RBC adhesion was also noted in a cohort consisting of
infants and young children with no HU therapy. These findings
suggest that increased HbF can inhibit, at least in part, RBC
adhesion in an HU-independent mechanism.

Figure 7. Proposed ICAM-1–mediated HbSS RBC
adhesion mechanism in SCD. Results are consistent
with a model of firm adhesion of HbSS RBCs to the
vasculature in the postcapillary venules under low
physiological shear, which may be mediated by initial
rolling adhesion of RBCs in the capillary under high
physiological shear, facilitated by ICAM-1. RBCs may
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which firm attachment is accomplished via integrins LFA-1 and
MAC-1.44 Meanwhile, in the case of P falciparum infection,
adhesion of iRBCs mediated by ICAM-1 causes rolling and static
adhesion over a wide range of shear rates.45 However, it was
reported that ICAM-1 was not able to successfully immobilize
iRBCs in the absence of CD36,46 which leads to the following
question: Why does ICAM-1 act as a rolling receptor and a firm
adhesion receptor? In accordance with previous discovery, we
reported the rolling behavior of HbSS RBCs on immobilized ICAM1, as well as that the ratio of rolling cells/firm adherent cells
increased with increasing shear rate. Because we have shown that
such HbSS RBC–ICAM-1 interaction is mediated by an intermediate molecule, fibrinogen, we speculate that the bridging of
fibrinogen to ICAM-1 might have a cutoff stress threshold, such that
the bond might be distorted under high shear and, thus, rupture
under a critical stress load. It is also likely that rolling RBCs may
have fewer adhesion receptors for fibrinogen on their membrane,
preventing them from establishing a firm attachment to ICAM-1
under high shear stress. Because reticulocytes have more binding
sites for fibrinogen,47,48 it is tempting to speculate that the majority
of firmly attached RBCs are younger relative to the rolling RBCs. On
the other hand, adhesion characteristics of HbSS RBCs onto
ICAM-1, whereby firm adhesion dominates under low shear rates
but rolling with increasing velocities occurs under high shear rates,
may provide unique insights into the mechanism of the initiation of
VOC-involved HbSS RBC–ICAM-1 interactions (Figure 7). We
postulate that, under inflammatory conditions in which endothelial
ICAM-1 levels are upregulated, HbSS RBCs roll in capillaries,
where the physiological shear rates are relatively higher, and firmly
attach to the vasculature in postcapillary venules where shear rates
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are lower, thus contributing to increased resistance to blood flow
and vaso-occlusion.
In conclusion, we used a physiologically relevant microfluidic
platform to quantitatively evaluate adhesion of HbSS RBCs to
immobilized ICAM-1. Our results pointed to a link between adhesion
levels and high-grade hemolysis, as well as a history of right-to-left
shunt development for subjects with HbSS SCD. Subjects with
higher HbF levels had a milder adhesion profile. We further
uncovered the role of plasma fibrinogen in mediating such HbSS
RBC–ICAM-1 interactions and characterized the motion of
adherent RBCs on ICAM-1, where they adhered firmly under low
shear rates but rolled with increasing velocities under high shear
rates. Future studies will aim to establish a physical model of HbSS
RBCs rolling on ICAM-1, including the role of fibrinogen. In addition
to HbSS SCD, the contribution that RBC adhesion to ICAM-1
might make to the pathophysiology of other diseases that include
abnormal RBC-endothelium interactions, such as diabetes and
retinal vein occlusion, warrants further investigation.
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